Alimera Sciences (NASDAQ: ALIM) and Auxilium Pharmaceuticals (NASDAQ:AUXL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares Alimera Sciences and Auxilium Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Alimera Sciences $35.96 million 2.67 -$16.78 million ($0.39) -3.56
Auxilium Pharmaceuticals N/A N/A N/A N/A N/A

Auxilium Pharmaceuticals has higher revenue, but lower earnings than Alimera Sciences.

Institutional and Insider Ownership

37.2% of Alimera Sciences shares are owned by institutional investors. 14.0% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Alimera Sciences and Auxilium Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alimera Sciences 0 0 3 0 3.00
Auxilium Pharmaceuticals 0 0 0 0 N/A

Alimera Sciences presently has a consensus target price of $4.00, indicating a potential upside of 187.77%. Given Alimera Sciences’ higher probable upside, equities research analysts plainly believe Alimera Sciences is more favorable than Auxilium Pharmaceuticals.

Profitability

This table compares Alimera Sciences and Auxilium Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alimera Sciences -68.58% N/A -36.39%
Auxilium Pharmaceuticals -29.78% -76.75% -11.59%

Summary

Alimera Sciences beats Auxilium Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

Alimera Sciences Company Profile

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Auxilium Pharmaceuticals Company Profile

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.